Biogen Inc. (BIIB) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - General Branche. Der Hauptsitz des Unternehmens ist in Cambridge, MA, United States. Der aktuelle CEO ist Christopher A. Viehbacher.
BIIB hat IPO-Datum 1991-09-17, 7,605 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $26.26B.
Biogen Inc. is a global biopharmaceutical company founded in 1978 and headquartered in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for neurological and neurodegenerative diseases. The company maintains a robust portfolio of approved treatments across multiple therapeutic areas, including multiple sclerosis (TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, OCREVUS), spinal muscular atrophy (SPINRAZA), Alzheimer's disease (ADUHELM), and oncology and immunology indications (RITUXAN, GAZYVA), alongside a growing biosimilar franchise featuring etanercept, adalimumab, and infliximab biosimilars. Beyond its marketed products, Biogen maintains an extensive pipeline of investigational therapies targeting neurological disorders, including candidates for multiple sclerosis, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease, and immunology-related conditions. The company leverages strategic collaborations with leading pharmaceutical and biotechnology partners including Genentech, Eisai, Ionis Pharmaceuticals, and Sage Therapeutics to advance its research and development initiatives across its core therapeutic focus areas.
